Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

115.16
-1.8400-1.57%
Volume:83.31K
Turnover:9.76M
Market Cap:9.58B
PE:-35.85
High:119.63
Open:118.40
Low:114.88
Close:117.00
52wk High:130.05
52wk Low:45.84
Shares:83.15M
Float Shares:64.87M
Volume Ratio:0.43
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.34
PE(LYR):-31.21

Loading ...

Kymera Therapeutics Inc - May Receive Tiered Royalties From High Single-Digit to Mid-Teens on Sales

THOMSON REUTERS
·
Apr 09

Kymera Therapeutics Inc - Eligible for up to $750 Mln in Total Payments Under Agreement

THOMSON REUTERS
·
Apr 09

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

GlobeNewswire
·
Apr 09

Kymera COO Jeremy G Chadwick disposes of USD 1.9 million common shares

Reuters
·
Apr 02

Kymera director Elena Ridloff disposes of USD 1.3 million common shares

Reuters
·
Apr 02

How Investors Are Reacting To Kymera Therapeutics (KYMR) Oral STAT6 Degrader’s Positive Phase 1b Atopic Dermatitis Data

Simply Wall St.
·
Mar 30

Kymera says oral STAT6 degrader KT-621 shows positive Phase 1b atopic dermatitis data

Reuters
·
Mar 28

Kymera Therapeutics Updates Bylaws on Federal Securities Litigation

TIPRANKS
·
Mar 28

Kymera Therapeutics amends bylaws; federal district courts named exclusive forum for Securities Act and Exchange Act claims

Reuters
·
Mar 28

Kymera Therapeutics; COO Jeremy G Chadwick disposes of common shares worth $9,033,226

Reuters
·
Mar 26

A Look At Kymera Therapeutics (KYMR) Valuation After Late Breaking KT-621 AAD 2026 Selection

Simply Wall St.
·
Mar 22

Kymera Therapeutics director Pamela Esposito disposes of USD 198,920 in common shares

Reuters
·
Mar 21

Kymera Therapeutics Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 17

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics

Reuters
·
Mar 16